Cat Allergy

20 registered clinical trials studyying Cat Allergy — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Viral Mucosal Reprogramming NCT05331170	The University of Texas Medical Branch, Galveston	Phase 2
Completed	Effectiveness of an Air Purifier on Asthmatic and Cat-allergic Subjects in the ALYATEC Environmental Exposure NCT06691568	Dyson Technology Ltd	N/A
Completed	Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy NCT04435678	MacroArray Diagnostics GmbH	N/A
Completed	Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduc NCT03838731	Regeneron Pharmaceuticals	Phase 2
Terminated	Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients NCT02959073	University of Zurich	—
Completed	A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy NCT02311413	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat All NCT02237196	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1 / Phase 2
Completed	Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients NCT02399579	University of Zurich	N/A
Completed	Phase III Cat-PAD Follow-on Study NCT02040844	Circassia Limited	Phase 3
Completed	An Optional Two Year Follow Up Study to Study CP005A NCT01604018	Circassia Limited	—
Completed	Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis NCT01383590	Circassia Limited	Phase 1
Completed	Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis NCT01383603	Circassia Limited	Phase 1
Terminated	Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Al NCT01292070	National Institute of Allergy and Infectious Diseases (NIAID)	EARLY_Phase 1
Completed	Cat-PAD Follow on Study NCT01272323	Circassia Limited	—
Completed	Cat-PAD Exposure Chamber Study NCT01033344	Circassia Limited	Phase 2
Completed	The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge NCT01003301	Johns Hopkins University	Phase 2
Completed	Exposure Chamber Trial With Cat Immunotherapy NCT00987909	ALK-Abelló A/S	Phase 2
Completed	Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma NCT00867906	Circassia Limited	Phase 2
Completed	Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects NCT00729508	Circassia Limited	Phase 2
Completed	Safety of Cat-PAD in Cat Allergic Subjects NCT00685711	Circassia Limited	Phase 1 / Phase 2